Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
Top Cited Papers
Open Access
- 1 September 2012
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (suppl_8), viii6-viii9
- https://doi.org/10.1093/annonc/mds256
Abstract
The immune system has the greatest potential for the specific destruction of tumours with no toxicity to normal tissue and for long-term memory that can prevent cancer recurrence. The last 30 years of immuno-oncology research have provided solid evidence that tumours are recognised by the immune system and their development can be stopped or controlled long term through a process known as immunosurveillance. Tumour specificity of the immune response resides in the recognition of tumour antigens. Viral proteins in tumours caused by viruses and mutated proteins from oncogenes or other genes, as well as nonmutated but abnormally expressed self proteins found on all tumours, have been shown to be good antigens and good targets for immunosurveillance. In many cancers, however, malignant progression is accompanied by profound immune suppression that interferes with an effective antitumour response and tumour elimination. Initially, most of the escape from immunosurveillance was ascribed to changes in the tumour cells themselves (loss of tumour antigens, loss of human leukocyte antigen molecules, loss of sensitivity to complement, or T cell or natural killer (NK) cell lysis), making them a poor target of an immune attack. However, it has become clear that the suppression comes from the ability of tumours to subvert normal immune regulation to their advantage. The tumour microenvironment can prevent the expansion of tumour antigen-specific helper and cytotoxic T cells and instead promote the production of proinflammatory cytokines and other factors, leading to the accumulation of suppressive cell populations that inhibit instead of promote immunity. The best described are regulatory T cells and myeloid-derived suppressor cells. Great conceptual and technical advances in the field of immuno-oncology over the past 30 years have provided us with the knowledge and techniques to develop novel immunotherapeutic approaches for the treatment of cancer. These include methods that enhance tumour immunity by blocking inhibitory pathways and inhibitory cells in the tumour microenvironment (e.g. antibodies against cytotoxic T-lymphocyte-associated antigen-4, programmed death 1 or its ligand programmed death ligand 1, or low-dose chemotherapy). Of equal importance, they include methods that can enhance the specificity of antitumour immunity by inducing the expansion of T cells and antibodies directed to well-defined tumour antigens (e.g. cancer vaccines, potent adjuvants, immunostimulatory cytokines). Even as monotherapies, these approaches are having a substantial impact on the treatment of some patients with advanced, previously untreatable, malignancies. Most exciting of all, these successes provide a rationale to expect that used in various combinations or earlier in disease, current and future immunotherapies may transform cancer treatment, improving a prognosis for many patients.Keywords
This publication has 18 references indexed in Scilit:
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel ImmunotherapySeminars in Oncology, 2010
- Features of responding T cells in cancer and chronic infectionCurrent Opinion in Immunology, 2010
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial NeoplasiaThe New England Journal of Medicine, 2009
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational ResearchClinical Cancer Research, 2009
- Cancer ImmunologyThe New England Journal of Medicine, 2008
- Immune surveillance: a balance between protumor and antitumor immunityCurrent Opinion in Genetics & Development, 2008